がん化学療法における副作用の解析 : 5-HT_3拮抗剤併用による便秘の発生について

概要

論文の詳細を見る
In order to prevent nausea and vomiting associated with cancer chemotherapy, 5-HT_3 antagonists are widely used. However, we noticed that the incidence of constipation following the co-administration of anticancer agents and 5-HT_3 antagonists in chemotherapy seemed to be higher than stated in the package inserts. To investigate this further, we sent a question-naire regarding constipation to patients who received cancer-chemotherapy at our hospital in which 5-HT_3 antagonists had been co-administered. We also investigated the degree of satisfaction of patients with the measures we took against constipation. The incidence of constipation was high (68%) on the day of cancer chemotherapy in which 5-HT_3 antagonists were co-administered, or on the following day. The incidence of constipation without the co-administration of 5-HT_3 antagonists was 6%. Among patients who experienced loss of appetite after cancer chemotherapy, 63% complained of constipation. There was a significant difference in the incidence of constipation between patients with loss of appetite and those with no loss of appetite. We feel that the high incidence of constipation following cancer chemotherapy was caused by the combination of the 5-HT_3 antagonists and a decreased food intake. Among patients with loss of appetite, 18% had difficulty in getting over the constipation and this suggests that the resulting lowered QOL could hinder the continuation of chemotherapy. We therefore consider that it is important to reduce adverse reactions in chemotherapy by administering preventive drugs thereby improving QOL.
日本医療薬学会の論文
2007-10-10

がん化学療法における副作用の解析 : 5-HT_3拮抗剤併用による便秘の発生について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク